| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1105978128 |
| P356 | DOI | 10.1186/S12933-018-0753-5 |
| P932 | PMC publication ID | 6071392 |
| P698 | PubMed publication ID | 30071874 |
| P50 | author | Frédéric Fumeron | Q41708076 |
| Gilberto Velho | Q44259397 | ||
| P2093 | author name string | Samy Hadjadj | |
| Stéphanie Ragot | |||
| Michel Marre | |||
| Ronan Roussel | |||
| Pierre-Jean Saulnier | |||
| Kamel Mohammedi | |||
| Louis Potier | |||
| Mathilde Fraty | |||
| Ray El Boustany | |||
| P2860 | cites work | A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin | Q21131156 |
| Science review: Vasopressin and the cardiovascular system part 1--receptor physiology | Q21195090 | ||
| A new equation to estimate glomerular filtration rate | Q24651973 | ||
| Vasopressin V1a and V1b receptors: from molecules to physiological systems | Q26823378 | ||
| The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group | Q28141968 | ||
| Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease | Q29037884 | ||
| Diabetes mellitus, fasting glucose, and risk of cause-specific death | Q33945937 | ||
| Copeptin in the differential diagnosis of hyponatremia | Q34014531 | ||
| Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus | Q34726918 | ||
| The effect of vasopressin infusion on glucose metabolism in man | Q69888813 | ||
| The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus | Q73733629 | ||
| Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial | Q88816312 | ||
| Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population | Q89574976 | ||
| The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. | Q44812728 | ||
| Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin | Q46790418 | ||
| The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels | Q47104362 | ||
| Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans | Q47676004 | ||
| Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. | Q47689985 | ||
| Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. | Q47741905 | ||
| Effect of increased water intake on plasma copeptin in healthy adults | Q47742757 | ||
| Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1A receptors. | Q48132369 | ||
| Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin | Q48895608 | ||
| All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. | Q50776124 | ||
| Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). | Q51035312 | ||
| Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort. | Q51102437 | ||
| Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. | Q51308854 | ||
| Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study | Q57052265 | ||
| Metabolic actions of vasopressin, glucagon and adrenalin in the intact rat | Q67322631 | ||
| ??? | Q28267062 | ||
| Copeptin is an independent predictor of diabetic heart disease and death | Q35433105 | ||
| Copeptin, Insulin Resistance, and Risk of Incident Diabetes in Older Men. | Q36060397 | ||
| Prognostic value of resting heart rate on cardiovascular and renal outcomes in type 2 diabetic patients: a competing risk analysis in a prospective cohort | Q36249527 | ||
| Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial | Q36329310 | ||
| Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). | Q36456306 | ||
| Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Dia | Q36842087 | ||
| Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community. | Q36965316 | ||
| Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study | Q37143797 | ||
| Plasma copeptin and the risk of diabetes mellitus | Q37147707 | ||
| The influence of body composition on renal function in patients with coronary artery disease and its prognostic significance: a retrospective cohort study | Q37148305 | ||
| Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome | Q37257539 | ||
| Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria | Q37278044 | ||
| Vasopressin: a novel target for the prevention and retardation of kidney disease? | Q38084471 | ||
| Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention | Q38111136 | ||
| Vasopressin and diabetic nephropathy. | Q38840338 | ||
| Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes | Q39301615 | ||
| Vasopressin and metabolic disorders: translation from experimental models to clinical use. | Q39422254 | ||
| Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. | Q39625891 | ||
| Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population | Q39652641 | ||
| Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort | Q39936653 | ||
| Gender and renal function influence plasma levels of copeptin in healthy individuals | Q40067883 | ||
| Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke | Q40235636 | ||
| Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study | Q40298924 | ||
| Copeptin predicts coronary artery disease cardiovascular and total mortality | Q41055703 | ||
| Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study | Q41394637 | ||
| The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives | Q41998074 | ||
| Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions | Q42141857 | ||
| Impact of renal function on the underlying pathophysiology of coronary plaque composition in patients with type 2 diabetes mellitus | Q42376671 | ||
| Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas | Q42525305 | ||
| Rapid stimulation by vasopressin, oxytocin and angiotensin II of glycogen degradation in hepatocyte suspensions | Q42935528 | ||
| Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients | Q43288503 | ||
| Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort | Q43684302 | ||
| Nephropathy in diabetes | Q44705106 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 110 | |
| P577 | publication date | 2018-08-02 | |
| P1433 | published in | Cardiovascular Diabetology | Q2468083 |
| P1476 | title | Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes | |
| P478 | volume | 17 |
| Q97073537 | Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers |
| Q90632812 | Distinguishing Low and High Water Consumers-A Paradigm of Disease Risk |
| Q64084205 | Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases |
| Q90465947 | Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes |
Search more.